This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
AuntMinnie
MARCH 15, 2024
An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Precision radiopharmaceuticals represent a step toward better, longer lifespans for all.
Radiology Business
JULY 12, 2024
For years, the agency has packaged payment for nuclear imaging agents with the procedure, but this has created a barrier for those who require pricier new drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Radiology Business
NOVEMBER 5, 2024
CMS is moving forward with a proposal to issue separate reimbursement for radiopharmaceuticals—a change long lobbied for by the imaging industry.
Radiology Business
JULY 14, 2023
The agency issued its solicitation as part of the 2024 Hospital Outpatient Prospective Payment System proposed rule, released late Thursday.
Radiology Business
JUNE 28, 2024
One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.
Radiology Business
NOVEMBER 20, 2024
The Australian company will secure exclusive worldwide rights to a suite of diagnostic and therapeutic candidates geared toward urological cancers.
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
305 
AuntMinnie
FEBRUARY 26, 2025
The new horizons of advanced imaging, especially in oncology, must increasingly consider not only diagnostic efficacy but also sustainability for patients, prize-winning researchers told ECR 2025 delegates. To mitigate these effects, low-energy imaging techniques should be prioritized without compromising diagnostic accuracy.
130 
Imaging Technology
NOVEMBER 7, 2024
Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures.
AuntMinnie
NOVEMBER 20, 2024
The company has entered into asset purchase and exclusive worldwide in-license agreements for a suite of clinically validated FAP-targeting therapeutic and precision medicine radiopharmaceutical candidates. Telix’s development program will initially focus on the treatment of bladder cancer.
130 
AuntMinnie
MARCH 27, 2025
Flyrcado delivers higher diagnostic efficacy compared with standard SPECT MPI,GE said. Pass-through payment status will allow the CMS to provide separate payments for the radiopharmaceutical and the PET-CT scan when performed with Flyrcado in the hospital outpatient setting. Food and Drug Administration (FDA) for the injection in 2024.Flyrcadois
130 
Diagnostic Imaging
NOVEMBER 15, 2024
In an interview, SNMMI president Cathy Cutler, PhD, discussed the impact of the recent CMS decision to unbundle reimbursement for diagnostic radiopharmaceuticals costing above $630 a day, calling it a “game changer” decision that will benefit patients, physicians, and the development of new radiopharmaceutical agents.
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. At the time, their cancer center served a significant cancer population in the region and maintained robust and ever-expanding PET diagnostics.
264 
AuntMinnie
SEPTEMBER 30, 2024
A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. Nearly 80% of patients in our study were progression-free after six months," he said.
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
264 
AuntMinnie
OCTOBER 17, 2023
Blue Earth Diagnostics and Sinotau Pharmaceutical have signed an agreement to distribute Blue Earth's Posluma (flotufolastat F-18) PET radiotracer in China.
130 
AuntMinnie
APRIL 4, 2024
Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.
Imaging Technology
JULY 9, 2024
Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Board of Directors.
105 
Imaging Technology
SEPTEMBER 20, 2023
a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.
105 
Imaging Technology
APRIL 10, 2024
an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,
Open Medscience
AUGUST 11, 2024
Radiopharmaceuticals in diagnostics provide critical insights into disease processes, improving accuracy, patient care, and treatment outcomes significantly. The post The Transformative Power of Radiopharmaceuticals in Diagnostics appeared first on Open MedScience.
AuntMinnie
MARCH 26, 2025
Centers for Medicare and Medicaid (CMS) to update the Hospital Outpatient Prospective Payment System (HOPPS) in 2025 by unbundling radiopharmaceuticals. Bera (D-CA) worked to include report language that promotes nuclear medicine research in the Department of Defenses (DOD) Congressionally Directed Medical Research Programs ( CDMRP ).
130 
Imaging Technology
JANUARY 5, 2024
The PSMA Alpha-PET DoubLET platform technology represents a potential leap forward in the field of prostate cancer diagnostics and treatment. We focused on diagnostic accuracy, patient tolerance and convenience. milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.
Open Medscience
FEBRUARY 28, 2024
Exploring the evolving role of radiopharmaceutical diagnostics in enhancing disease detection and personalising treatment in modern medicine. The post Radiopharmaceutical Diagnostics and Imaging Technologies appeared first on Open Medscience.
AuntMinnie
SEPTEMBER 25, 2024
Centers for Medicare and Medicaid Services (CMS) to “unbundle” payments for diagnostic radiopharmaceuticals from the cost of nuclear medicine tests, cardiac SPECT procedures may get the short end of the stick, said Lawrence Phillips, MD, of NYU Langone Health in New York City, in an interview with AuntMinnie.com.
AuntMinnie
OCTOBER 25, 2024
He earned his medical degree at the University of Alabama School of Medicine and completed a residency in diagnostic radiology at the University of Florida. An assistant professor of radiology and radiological science, Francis Deng, MD, is the Johns Hopkins radiology department's co-director of medical student diagnostic radiology electives.
358 
Imaging Technology
JULY 25, 2023
By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."
AuntMinnie
NOVEMBER 12, 2024
He earned his medical degree at the University of Alabama School of Medicine and completed a residency in diagnostic radiology at the University of Florida. Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year. from Ukraine.
360 
Imaging Technology
JUNE 15, 2023
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.
Imaging Technology
DECEMBER 6, 2023
and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.
105 
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
306 
Open Medscience
JANUARY 1, 2024
Zirconium radiopharmaceuticals enhance nuclear medicine with precise diagnostics and potential therapeutic applications. The post Zirconium Radiopharmaceuticals in Nuclear Medicine appeared first on Open Medscience.
Open Medscience
NOVEMBER 17, 2023
Gallium, predicted by Mendeleev, now revolutionises medical diagnostics with its unique radiopharmaceutical applications in oncology. The post Gallium Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
130 
Open Medscience
DECEMBER 31, 2023
Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities. The post Lutetium Radiopharmaceuticals in Medicine: A Comprehensive Review appeared first on Open Medscience.
AuntMinnie
FEBRUARY 19, 2025
Food and Drug Administration (FDA) for its copper-67 (Cu-67) SAR-bisPSMA radiopharmaceutical for treating advanced prostate cancer. The classification builds on Clarity's earlier receipt of fast-track designation for its PET diagnostic imaging agent Cu-64 SAR-bisPSMA for identifying patients with the disease.
Imaging Technology
JULY 11, 2023
We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By
AuntMinnie
FEBRUARY 12, 2024
In this large, real-world study, we found that [beta amyloid]-PET led to the changes in etiological diagnosis, diagnostic confidence, and treatment plan, providing new evidence for the use of [amyloid beta]-PET in Chinese population,” the group wrote. of patients, noted lead author Ke-Liang Chen, MD, a neurologist at Fudan University. “In
262 
AuntMinnie
JANUARY 3, 2024
NorthStar Medical Radioisotopes and Chester Springs, PA-based Curadh MTR have entered a strategic collaboration agreement to develop radiopharmaceuticals for the treatment of primary and metastatic solid tumors.
Open Medscience
NOVEMBER 11, 2023
Copper radiopharmaceuticals offer groundbreaking diagnostic and therapeutic applications, revolutionising nuclear medicine, particularly in oncology and cardiology. The post Exploring Copper Radiopharmaceuticals: Innovations and Applications in Nuclear Medicine appeared first on Open Medscience.
AuntMinnie
JUNE 20, 2024
To establish which of the two is the optimal first-line approach, the group enrolled 57 patients (63 years old on average; 15 men and 42 women) in a multicenter randomized diagnostic intervention trial. Between November 2019 and May 2022, patients received first-line FCH-PET/CT (n = 29) or MIBI-SPECT/CT (n = 28) prior to surgery.
Open Medscience
NOVEMBER 12, 2023
Technetium-99m, discovered in 1937, transformed medical imaging with its versatile and safe diagnostic applications. The post Technetium-99m Radiopharmaceuticals in Advanced Medical Imaging appeared first on Open Medscience.
AuntMinnie
MARCH 27, 2025
Flyrcado delivers higher diagnostic efficacy compared with standard SPECT MPI,GE said. Pass-through payment status will allow the CMS to provide separate payments for the radiopharmaceutical and the PET-CT scan when performed with Flyrcado in the hospital outpatient setting. Food and Drug Administration (FDA) for the injection in 2024.Flyrcadois
147 
AuntMinnie
MAY 17, 2023
The Facilitating Access to Innovative Diagnostics (FIND) Act -- legislatio. Read more on AuntMinnie.com Related Reading: FIND Act reintroduced in Congress MITA hails radiopharmaceutical legislation SNMMI supports new legislation to fix PET payment policy Molecular imaging saw wins, losses over past year
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content